What is the future of immunotherapy in multiple myeloma?
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
26 11 2020
26 11 2020
Historique:
received:
13
05
2020
accepted:
17
07
2020
pubmed:
1
8
2020
medline:
7
4
2021
entrez:
1
8
2020
Statut:
ppublish
Résumé
The treatment of multiple myeloma (MM) is currently being redefined by humoral and cellular immunotherapies. For decades, there was limited belief in immune-based anti-MM therapy as a result of the moderate graft-versus-myeloma effect of allogeneic stem cell transplantation. Today, monoclonal antibodies comprise the new backbone of anti-MM therapy, and T-cell therapies targeting BCMA are emerging as the most potent single agents for MM treatment. Herein, we present our assessment of and vision for MM immunotherapy in the short and midterm.
Identifiants
pubmed: 32735639
pii: S0006-4971(20)81974-0
doi: 10.1182/blood.2019004176
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2491-2497Informations de copyright
© 2020 by The American Society of Hematology.